Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of BI 836880 Administered by Weekly Repeated Intravenous Infusions in Patients With Advanced Solid Tumors

Trial Profile

Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of BI 836880 Administered by Weekly Repeated Intravenous Infusions in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Feb 2018

At a glance

  • Drugs BI 836880 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 06 Feb 2018 Planned End Date changed from 12 Aug 2018 to 19 Feb 2019.
    • 06 Feb 2018 Planned primary completion date changed from 29 Jul 2018 to 12 Feb 2019.
    • 22 Jan 2018 Planned End Date changed from 29 Jul 2018 to 12 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top